


What is claimed is:

1. A compound of formula (I):



(I),


or a pharmaceutically acceptable salt, tautomer, isotopolog, or stereoisomer thereof,
wherein:

Ring A is an optionally substituted non-aromatic heterocyclyl;

each R is independently substituted or unsubstituted C_{1-3} alkyl, or halogen; and

n is 0, 1, 2, 3 or 4.


2. The compound of claim 1, wherein the compound is a compound of formula (II):



(II),

or a pharmaceutically acceptable salt, tautomer, isotopolog, or stereoisomer thereof.


3. The compound of claim 1, wherein the compound is a compound of formula (III):



(III),

or a pharmaceutically acceptable salt, tautomer, isotopolog, or stereoisomer thereof.


4. The compound of claim 1, wherein the compound is a compound of formula (IV):



(IV),

or a pharmaceutically acceptable salt, tautomer, or isotopolog thereof.


5. The compound of claim 4, wherein the compound is a compound of formula (V):



(V),

or a pharmaceutically acceptable salt, tautomer, or isotopolog thereof.


6. The compound of claim 4, wherein the compound is a compound of formula (VI):



(VI),

or a pharmaceutically acceptable salt, tautomer, or isotopolog thereof.


7. The compound of claim 1, wherein the compound is a compound of formula (VII):



(VII),

or a pharmaceutically acceptable salt, tautomer, or isotopolog thereof.


8. The compound of claim 7, wherein the compound is a compound of formula (VIII):



(VIII),

or a pharmaceutically acceptable salt, tautomer, or isotopolog thereof.


9. The compound of claim 7, wherein the compound is a compound of formula (IX):



(IX),


or a pharmaceutically acceptable salt, tautomer, or isotopolog thereof.

10. The compound of any one of claims 1–9, wherein Ring A is




wherein R^a is H, and R^b is C_{1-6} alkyl, non-aromatic heterocyclyl, aryl, heteroaryl, or O-aryl; or R^a and R^b together with the carbon to which they are attached form a 3-6 membered cycloalkyl, or a 4-6 membered non-aromatic heterocyclyl; wherein the alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl are optionally substituted with one or more halogen, C_{1-3} alkyl, or CN.

11. The compound of any one of claims 1–9, wherein Ring A is



wherein R^c is H, halogen, OH, or (C_{1-3} alkyl); and R^d is optionally substituted (C_{1-3} alkyl), OR^1 , $C(O)N(R^2)_2$, $SO_2(C_{1-4}$ alkyl), C_{3-7} cycloalkyl, non-aromatic heterocyclyl, aryl, heteroaryl, or O-heteroaryl; or R^c and R^d together with the carbon to which they are attached form a 3-6 membered cycloalkyl, or a 4-6 membered non-aromatic heterocyclyl; wherein R^1 is H, optionally substituted C_{1-6} alkyl, or optionally substituted $-(C_{0-3}$ alkyl)-(C_{3-7} cycloalkyl); each R^2 is independently H, or C_{1-6} alkyl; and wherein the alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl are optionally substituted with one or more halogen, C_{1-3} alkyl, or CN.

12. The compound of any one of claims 1–9, wherein Ring A is



wherein R^e is C_{1-6} alkyl, $SO_2(C_{1-4}$ alkyl), $-(C_{0-3}$ alkyl)-(C_{3-7} cycloalkyl), aryl, heteroaryl or CO-aryl; wherein the alkyl, cycloalkyl, aryl, or heteroaryl are optionally substituted.

13. The compound of any one of claims 1–9, wherein Ring A is an optionally substituted non-aromatic heterocyclyl selected from azetidyl; piperidyl; piperazinyl;

morpholinyl; 5-azaspiro[2,3]hexyl; 2-azaspiro[3.3]heptyl; 2-oxa-6-azaspiro[3.3]heptyl; 2-azaspiro[3.4]octyl; 5-oxa-2-azaspiro[3.4]octyl; 6-oxa-2-azaspiro[3.4]octyl; 2-azaspiro[3.5]nonyl; 7-oxa-2-azaspiro[3.5]nonyl; octahydrocyclopenta[c]pyrrolyl; 1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrolyl; 6-azaspiro[3.4]octyl; 2-oxa-6-azaspiro[3.4]octyl; 6-azaspiro[2.5]octyl; 7-azaspiro[3.5]nonyl; 1-oxa-8-azaspiro[4.5]decanyl; 2-oxa-8-azaspiro[4.5]decanyl; 2,8-diazaspiro[4.5]decan-1-onyl; 3-oxa-9-azaspiro[5.5]undecanyl; 1,4-oxazepanyl; 8-azabicyclo[3.2.1]octyl; and isoindolinyl.

14. The compound of claim 13, wherein Ring A is substituted with one or more substituents independently selected from halogen, C₁₋₆ alkyl, OR¹, CON(R²)₂, SO₂(C₁₋₄ alkyl), N(R²)SO₂(C₁₋₄ alkyl), -(C₀₋₃ alkyl)-(C₃₋₇ cycloalkyl), (non-aromatic heterocyclyl), aryl, heteroaryl, O-aryl, O-heteroaryl, and C(O)aryl; wherein the alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl are optionally substituted; wherein R¹ is H, optionally substituted C₁₋₆ alkyl, or optionally substituted -(C₀₋₃ alkyl)-(C₃₋₇ cycloalkyl); and each R² is independently H, or C₁₋₆ alkyl.

15. The compound of claim 13, wherein Ring A is substituted with one or more substituents independently selected from F, Cl, Br, CH₃, CH₂CH₃, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, CH₂F, CHF₂, CF₃, CH₂CH₂F, CH₂CHF₂, CH₂CF₃, CH(CH₃)CF₃, CH₂CH₂CF₃, OH, OCH₃, OCH₂CH₃, O-isopropyl, O-n-propyl, O-n-butyl, O-isobutyl, O-t-butyl, OCF₃, O-cyclopropyl, O-cyclobutyl, OCH₂cyclopropyl, OCH₂cyclobutyl, CONH₂, CONH(CH₃), CON(CH₃)₂, SO₂CH₃, SO₂CH₂CH₃, SO₂-isopropyl, cyclopropyl, cyclobutyl, CH₂-cyclopropyl, CH₂-cyclobutyl; (non-aromatic heterocyclyl) selected from azetidyl, pyrrolidyl, pyrrolidonyl, isothiazolidyl, isothiazolidine 1,1-dioxidyl, piperidyl, piperazinyl, morpholinyl, 3-oxa-8-azabicyclo[3.2.1]octyl, or 8-oxa-3-azabicyclo[3.2.1]octyl, wherein the heterocyclyl is optionally substituted with one or more substituents independently selected from CH₃, CH₂CH₃, or CF₃; phenyl, O-phenyl or C(O)-phenyl, wherein the phenyl is optionally

substituted with one or more substituents independently selected from F, Cl, CH₃, CN, or CONH₂; heteroaryl selected from pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidyl, or benzoisoxazolyl, wherein the heteroaryl is optionally substituted with one or more substituents independently selected from F, Cl, CF₃, CN, CONH₂, CONH(CH₃) or CON(CH₃)₂; O-pyridyl, and O-pyrimidyl.

16. The compound of claim 13, wherein Ring A is substituted with one or more substituents independently selected from F, CH₃, CH₂CH₃, isopropyl, t-butyl, CH₂F, CF₃, CH(CH₃)CF₃, OH, OCH₃, OCH₂CH₃, O-isopropyl, O-n-propyl, O-isobutyl, O-t-butyl, OCF₃, O-cyclobutyl, OCH₂cyclopropyl, CON(CH₃)₂, SO₂CH₂CH₃, SO₂-isopropyl, cyclopropyl, cyclobutyl, CH₂-cyclopropyl; (non-aromatic heterocyclyl) selected from pyrrolidyl, pyrrolidonyl, isothiazolidine 1,1-dioxidyl, morpholinyl, 3-oxa-8-azabicyclo[3.2.1]octyl, or 8-oxa-3-azabicyclo[3.2.1]octyl, wherein the heterocyclyl is optionally substituted with one or more substituents independently selected from CH₃, phenyl, O-phenyl or C(O)-phenyl, wherein the phenyl is optionally substituted with one or more substituents independently selected from F, Cl, CH₃, CN, or CONH₂; heteroaryl selected from pyrazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrazinyl, pyrimidyl or benzoisoxazolyl, wherein the heteroaryl is optionally substituted with one or more substituents independently selected from F, Cl, CF₃, CN, CONH₂, CON(CH₃)₂; O-pyridyl, and O-pyrimidyl.

17. The compound of claim 13, wherein Ring A is azetidyl, substituted with one or more substituents independently selected from C₁₋₆ alkyl, (non-aromatic heterocyclyl), aryl, heteroaryl, O-aryl, and O-heteroaryl; wherein the alkyl, heterocyclyl, aryl, or heteroaryl are optionally substituted.

18. The compound of claim 13, wherein Ring A is azetidyl, substituted with one or more substituents independently selected from CH₂CH₃, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl; CF₃; pyrrolidyl; pyrrolidonyl; piperidyl; piperazinyl; morpholinyl,

optionally substituted with one or more CH₃; 3-oxa-8-azabicyclo[3.2.1]octyl; 8-oxa-3-azabicyclo[3.2.1]octyl; pyrazolyl; 2-pyridyl; 3-pyridyl; 4-pyridyl, phenyl; and O-phenyl; wherein the phenyl optionally is substituted with one or more substituents selected from F or CN.

19. The compound of claim 13, wherein Ring A is piperidyl, substituted with one or more substituents independently selected from halogen, C₁₋₆ alkyl, OR¹, CON(R²)₂, SO₂(C₁₋₄ alkyl), C₃₋₇ cycloalkyl, non-aromatic heterocyclyl, aryl, heteroaryl and O-heteroaryl; wherein the alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl are optionally substituted; wherein R¹ is H, optionally substituted C₁₋₆ alkyl, or optionally substituted - (C₀₋₃ alkyl)-(C₃₋₇ cycloalkyl); and each R² is independently H, or C₁₋₆ alkyl.

20. The compound of claim 13, wherein Ring A is piperidyl, substituted with one or more substituents independently selected from F, Cl, CH₃, CH₂CH₃, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, CH₂F, CHF₂, CF₃, OH, OCH₃, OCH₂CH₃, O-n-propyl, O-isopropyl, O-n-butyl, O-isobutyl, O-t-butyl, OCF₃, O-cyclopropyl, O-cyclobutyl, OCH₂-cyclopropyl, OCH₂-cyclobutyl, CONH₂, CONH(CH₃), CON(CH₃)₂, SO₂CH₃, SO₂CH₂CH₃, SO₂-isopropyl, cyclopropyl, cyclobutyl, pyrrolidonyl, isothiazolidine 1,1-dioxidyl, morpholinyl; tetrahydrofuranyl, tetrahydropyranyl, pyrazolyl; oxadiazolyl, optionally substituted with CH₃; phenyl, optionally substituted with one or more F; 2-pyridyl, 3-pyridyl, 4-pyridyl, O-2-pyridyl, O-3-pyridyl, and O-4-pyridyl.

21. The compound of claim 13, wherein Ring A is piperidyl, substituted with one or more substituents independently selected from F, CH₃, CH₂CH₃, isopropyl, t-butyl, CHF₂, CF₃, OH, OCH₃, OCH₂CH₃, O-isopropyl, O-isobutyl, O-t-butyl, OCF₃, O-cyclobutyl, OCH₂-cyclopropyl, CON(CH₃)₂, SO₂CH₂CH₃, SO₂-isopropyl, cyclopropyl, pyrrolidonyl, isothiazolidine 1,1-dioxidyl, morpholinyl; tetrahydropyranyl, pyrazolyl, oxadiazolyl, substituted with CH₃; phenyl, substituted with one or more F; 2-pyridyl, and O-2-pyridyl.

22. The compound of claim 13, wherein Ring A is piperazinyl, substituted with one or more substituents independently selected from C₁₋₆ alkyl, SO₂(C₁₋₄ alkyl), -(C₀₋₃ alkyl)-(C₃₋₇ cycloalkyl), aryl, heteroaryl and CO-aryl; wherein the alkyl, cycloalkyl, aryl, or heteroaryl are optionally substituted.

23. The compound of claim 13, wherein Ring A is piperazinyl, substituted with one or more substituents independently selected from CH₃, CH₂CH₃, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, CF₃, CH₂CF₃, CH(CH₃)CF₃, SO₂CH₃, SO₂CH₂CH₃, SO₂-isopropyl, cyclopropyl, cyclobutyl, (CH₂)cyclopropyl, (CH₂)cyclobutyl, phenyl, optionally substituted with one or more Cl, F, CN, CH₃, CONH₂; pyrazolyl, optionally substituted with CH₃ or CH₂CH₃; oxazolyl, optionally substituted with CH₃ or CH₂CH₃; oxadiazolyl, optionally substituted with CH₃ or CH₂CH₃; thiadiazolyl, optionally substituted with CH₃, CH₂CH₃, or CF₃; 2-pyridyl, 3-pyridyl, or 4-pyridyl, each optionally substituted with Cl, F, CF₃, CN, CONH₂, CONH(CH₃) or CON(CH₃)₂; pyrazinyl, optionally substituted with CH₃ or CH₂CH₃; pyrimidyl, optionally substituted with OCH₃; benzoisoxazolyl; and CO(phenyl), wherein the phenyl is optionally fluorinated.

24. The compound of claim 13, wherein Ring A is piperazinyl, substituted with one or more substituents independently selected from CH₃, isopropyl, t-butyl, CH(CH₃)CF₃, SO₂CH₂CH₃, SO₂-isopropyl, cyclopropyl, cyclobutyl, (CH₂)cyclopropyl, phenyl, optionally substituted with one or more Cl, F, CN, CH₃, CONH₂; pyrazolyl, optionally substituted with CH₃; oxazolyl, optionally substituted with CH₃; oxadiazolyl, optionally substituted with CH₂CH₃; thiadiazolyl, optionally substituted with CH₃, or CH₂CH₃; 2-pyridyl, optionally substituted with Cl, F, CF₃, CN, or CONH₂; 3-pyridyl, optionally substituted with CF₃, CN, CONH₂, or CON(CH₃)₂; 4-pyridyl, optionally substituted with CONH₂; pyrazinyl, optionally substituted with CH₃; pyrimidyl, optionally substituted with OCH₃; benzoisoxazolyl; and CO(phenyl), wherein the phenyl is optionally fluorinated.

25. The compound of claim 13, wherein Ring A is morpholinyl, and R is F or CH₃, and n is 1.




26. The compound of claim 13, wherein Ring A is selected from 5-azaspiro[2,3]hexyl; 2-azaspiro[3.3]heptyl; 2-oxa-6-azaspiro[3.3]heptyl; 2-azaspiro[3.4]octyl; 5-oxa-2-azaspiro[3.4]octyl; 6-oxa-2-azaspiro[3.4]octyl; 2-azaspiro[3.5]nonyl; 7-oxa-2-azaspiro[3.5]nonyl; octahydrocyclopenta[c]pyrrolyl; 1,2,3,3a,4,6a-hexahydrocyclopenta[c]pyrrolyl; 6-azaspiro[3.4]octyl; 2-oxa-6-azaspiro[3.4]octyl; 6-azaspiro[2.5]octyl; 7-azaspiro[3.5]nonyl; 1-oxa-8-azaspiro[4.5]decanyl; 2-oxa-8-azaspiro[4.5]decanyl; 2,8-diazaspiro[4.5]decan-1-onyl; 3-oxa-9-azaspiro[5.5]undecanyl; 1,4-oxazepanyl; 8-azabicyclo[3.2.1]octyl; and isoindolinyl; each optionally substituted with one or more CH₃ or F.


27. The compound of any one of claims 1–26, wherein R is F.

28. The compound of any one of claims 1–26, wherein R is CH₃.


29. The compound of any one of claims 1–28, wherein n is 1.

30. The compound of claim 1, which is:







Compound 4,




Compound 5,




Compound 6,




Compound 7,




Compound 8,




Compound 9,




Compound 10,




Compound 11,




Compound 12,




Compound 13,




Compound 14,




Compound 15,




Compound 16,




Compound 17,




Compound 18,




Compound 19,




Compound 20,




Compound 21,




Compound 22,




Compound 23,




Compound 24,




Compound 25,




Compound 26,




Compound 27,




Compound 28,




Compound 29,




Compound 30,




Compound 31,




Compound 32,




Compound 33,




Compound 34,




Compound 35,




Compound 36,




Compound 37,




Compound 38,




Compound 39,




Compound 40,




Compound 41,




Compound 42,




Compound 43,




Compound 44,




Compound 45,




Compound 46,




Compound 47,




Compound 48,




Compound 49,




Compound 50,




Compound 51,




Compound 52,




Compound 53,




Compound 54,




Compound 55,




Compound 56,




Compound 57,




Compound 58,




Compound 59,




Compound 60,




Compound 61,




Compound 62,




Compound 63,




Compound 64,




Compound 65,




Compound 66,




Compound 67,




Compound 68,




Compound 69,




Compound 70,




Compound 71,




Compound 72,




Compound 73,




Compound 74,




Compound 75,




Compound 76,




Compound 77,




Compound 78,




Compound 79,




Compound 80,




Compound 81,




Compound 82,




Compound 83,




Compound 84,




Compound 85,




Compound 86,




Compound 87,




Compound 88,




Compound 89,




Compound 90,




Compound 91,




Compound 92,




Compound 93,




Compound 94,




Compound 95,




Compound 96,




Compound 97,




Compound 98




Compound 99,




Compound 100,




Compound 101,




Compound 102,




Compound 103,




Compound 104,




Compound 105,




Compound 106,




Compound 107,




Compound 108,




Compound 109,




Compound 110,




Compound 111,




Compound 112,




Compound 113,




Compound 114,




Compound 115,




Compound 116,




Compound 117,




Compound 118,




Compound 119,




Compound 120,




Compound 121,




Compound 122,




Compound 123,




Compound 124,




Compound 125,




Compound 126,




Compound 127,




Compound 128,




Compound 129,




Compound 130,




Compound 131,




Compound 132,




Compound 133,




Compound 134,




Compound 135,




Compound 136,




Compound 137,




Compound 138,




Compound 139,




Compound 140,




Compound 141,




Compound 142,




Compound 143,




Compound 144,




Compound 145,




Compound 146,




Compound 147,




Compound 148,




Compound 149,




Compound 150,




Compound 151,




Compound 152,




Compound 153,




Compound 154,




Compound 155,




Compound 156,




Compound 157,




Compound 158,




Compound 159,




Compound 160,




Compound 161,




Compound 162,




Compound 163,




Compound 164,




Compound 165,




Compound 166,




Compound 167,




Compound 168,




Compound 169,




Compound 170,




Compound 171,




Compound 172,




Compound 173,




Compound 174,




Compound 175,




Compound 176,




Compound 177,




Compound 178,




Compound 179,




Compound 180,




Compound 181,




Compound 182,




Compound 183,




Compound 184,




Compound 185,




Compound 186,




Compound 187,




Compound 188,




Compound 189,




Compound 190,




Compound 191,




Compound 192,




Compound 193,




Compound 194,




Compound 195,




Compound 196,




Compound 197,




Compound 198,




Compound 199,




Compound 200,




Compound 201,




Compound 202,




Compound 203,




Compound 204,




Compound 205,




Compound 206,




Compound 207,




Compound 208,




Compound 209,




Compound 210,




Compound 211,




Compound 212,




Compound 213,




Compound 214,




Compound 215,




Compound 216,




Compound 217,




Compound 218,




Compound 219,




Compound 220,




Compound 221,




Compound 222,




Compound 223,




Compound 224,




Compound 225,




Compound 226,




Compound 227,




Compound 228,




Compound 229,




Compound 230,




Compound 231,




Compound 232,




Compound 233,




Compound 234,




Compound 235,




Compound 236,




Compound 237,




Compound 238,




Compound 239,




Compound 240,




Compound 241,




Compound 242,




Compound 243,




Compound 244,




Compound 245,




Compound 246,



Compound 247,




Compound 248, or



Compound 249,


or a pharmaceutically acceptable salt thereof.

31. A compound, which is




or a pharmaceutically acceptable salt thereof.

32. The compound of claim 31, which is




33. A compound, which is



or a pharmaceutically acceptable salt thereof.

34. The compound of claim 33, which is




35. A pharmaceutical composition comprising an effective amount of a compound of any one of claims 1–34, or a pharmaceutically acceptable salt, tautomer, isotopologue, or stereoisomer thereof, and a pharmaceutically acceptable carrier, excipient or vehicle.

36. Use of a compound of any one of claims 1–34, or a pharmaceutical composition of claim 35 in the manufacture of a medicament for the treatment of diffuse large B-cell lymphoma (DLBCL).


37. The use of claim 36, wherein the DLBCL is relapsed or refractory DLBCL.

38. The use of claim 37, wherein the DLBCL is refractory to one or more of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide, bendamustine, lenalidomide, or gemcitabine.
39. The use of claim 36, wherein the DLBCL is newly diagnosed DLBCL.
40. The use of any one of claims 36–39, wherein the medicament is for use in combination with one or more of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide, bendamustine, lenalidomide, or gemcitabine.
41. A method for preparing a compound of formula (I):



(I)

the method comprising contacting a compound of formula (Ia):



(Ia),

with



in the presence of a base, in a solvent, under conditions suitable to provide a compound of formula (I), wherein

Ring A is an optionally substituted non-aromatic heterocyclyl;

each R is independently substituted or unsubstituted C₁₋₃ alkyl, or halogen;

n is 0, 1, 2, 3 or 4; and

LG is OMs, OTs, or halogen.